Lumbar disc disease (LDD) is a common musculoskeletal disorder, caused by degeneration of intervertebral discs of the lumbar spine and is one of the most common musculoskeletal disorders affliction in adult. There is growing evidence that LDD has strong genetic determinants. We analyze whether the IL4 and IL6 gene polymorphism is related to LDD in Chinese Han population. The participants were 498 with LDD and 463 without LDD. IL4 and IL6 gene polymorphism were determined by Sequenom MassARRAY. We found that SNPs rs1800796(OR = 1.29, 95% CI, 1.07 - 1.57, p = 0.009), rs1524107(OR = 1.28, 95% CI, 1.05 - 1.55, p = 0.013), rs2069840 (OR = 1.39, 95% CI, 1.03 - 1.89, p = 0.033) in IL6 gene were significantly associated with LDD risk at a 5% level. In addition, genetic models found IL4 gene (rs2243250) were associated with LDD. In this study, we analyzed and associated SNPs of IL4 and IL6 with LDD risk. In summary, four variations (rs1800796, rs1524107, rs2069840, rs2243250) of the selected candidate SNPs were associated with susceptibility to LDD in our study. The results of this study have the guiding significance in clinical work in the future in the treatment of lumbar disc herniation patients, not one-sided that the symptoms of low back pain only from mechanical oppression.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5687669PMC
http://dx.doi.org/10.18632/oncotarget.21650DOI Listing

Publication Analysis

Top Keywords

il4 il6
16
il6 gene
16
gene polymorphism
12
lumbar disc
12
ldd
9
common musculoskeletal
8
associated ldd
8
ldd risk
8
ldd study
8
il6
5

Similar Publications

Mycobacterium tuberculosis (M. tuberculosis) and Mycobacterium abscessus (M. abscessus) are important pathogens that can cause lung diseases.

View Article and Find Full Text PDF

Biomarkers.

Alzheimers Dement

December 2024

Department of Neurology & Innovation Center for Neurological Disorders, Xuanwu Hospital, Capital Medical University, National Center for Neurological Disorders, Beijing, Beijing, China.

Background: Blood biomarkers provide a non-invasive and accessible means of detection for Alzheimer's disease (AD). Specifically, biomarkers associated with early-onset AD (EOAD) illuminate the underlying mechanisms and provide valuable guidance for potential therapies. We aim to present blood biomarker evidence in individuals with both EOAD and late-onset AD (LOAD), as well as in age-matched healthy controls.

View Article and Find Full Text PDF

Biomarkers.

Alzheimers Dement

December 2024

UNICAMP, Campinas, Brazil; Sao Leopoldo Mandic Araras School of Medicine, Araras, Brazil; USP - University of Sao Paulo, Ribeirao Preto, Brazil.

Background: Neuroinflammation can be considered a risk factor for the onset or progression of Alzheimer's dementia. In a neuroinflammatory process, the death of neurons may accelerate, favoring the progression of Alzheimer's disease. The release of pro-inflammatory proteins can, for example, cause synaptic dysfunction and impede neurogenesis.

View Article and Find Full Text PDF

Biomarkers.

Alzheimers Dement

December 2024

The Pennsylvania State University, University Park, PA, USA.

Background: Inflammation is a risk factor for cognitive decline, mild cognitive impairment (MCI), and Alzheimer's disease (AD). While past research in laboratory settings suggests that inflammation relates to cognitive decline and MCI status, more research is needed to examine such associations in everyday life. The present work addressed this gap by examining MCI and gender stratified links between circulating inflammatory biomarkers and self-reported prospective memory (PM; i.

View Article and Find Full Text PDF

Background: Patients with rapid progressive Alzheimer disease and related dementias (rpAD/ADRD) develop dementia within 1 year or incapacitation within 2 years of symptom onset. We previously showed that selected CSF biomarkers of neuronal injury (NfL, VILIP-1), AD neuropathology (p-tau181), and neuroinflammation (GFAP, MCP-1, sTREM2) measured at presentation associated with etiologic diagnoses and reliably differentiated patients with treatment-responsive causes of rapid progressive dementia. However, no differences were identified between CSF biomarkers in patients with rapid and typical progressive forms of AD/ADRD, leaving key questions unanswered concerning the mechanisms that drive rpAD/ADRD.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!